All In Biotech

Drug Trial Radar · NCT03499873

Clinical Endpoint Study of Nepafenac 0.3% Opthalmic Suspension

A Randomized, Multicenter, Double Masked, Placebo Controlled, Parallel Group, Bioequivalence Study to Evaluate the Clinical Equivalence and Safety of Nepafenac 0.3% Ophthalmic Suspension (Manufactured by Indoco Remedies Ltd. for Actavis LLC) With IlevroTM (Nepafenac Ophthalmic Suspension), 0.3% of Alcon Laboratories, Inc. for the Treatment of Pain and Inflammation Associated With Cataract Surgery.

Last checked: Nov 20, 2026Latest source record: Feb 16, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 448 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

448

Actual

Start

Mar 28, 2018

Primary completion

Oct 31, 2018

Study completion Dec 18, 2018

Sponsor

Lead sponsor
Actavis Inc.Industry
Sponsor type
Industry
First posted
Apr 17, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A randomized, multicenter, double masked, placebo controlled, parallel group, bioequivalence study to evaluate the clinical equivalence and safety of Nepafenac 0.3% ophthalmic suspension (manufactured by Indoco remedies Ltd. for Actavis LLC) with IlevroTM (Nepafenac ophthalmic suspension), 0.3% of Alcon Laboratories, Inc. for the treatment of pain and inflammation associated with cataract surgery.

Conditions

  • Cataract

Interventions

  • Nepafenac 0.3% Oph SuspDrug

    Nepafenac 0.3% Ophthalmic suspension (experimental product)

  • PlacebosDrug

    Placebo

  • Nepafenac 0.3% Oph Susp (reference)Drug

    Nepafenac 0.3% Ophthalmic suspension (Innovator)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cure at Day 14Time frame: 14 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Key-Whitman Eye Center

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.